Mold-Tek Packaging Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/et1ggeihendlmrdh9uue0ioi.pdf

Key Takeaways


Volume & Segment Performance

Lakshmana Rao: "None of the big players would go for that because they know they need in season capacities and volumes and also uninterrupted supplies. So, like what we - happens in the paint industry might happen over the next five to seven years in the food industry where you will have more pockets of competition coming up."

Margin Walk & Cost Pressures

Lakshmana Rao: "Actually, we are taking up this point with all the top paint companies. Even our competitors are speaking that if you need to add RCP material, you also need to change the conversion prices. So, that discussion has just started. Probably in next few quarters, we may try to convince them for increasing the conversion price."

Pharma Packaging: The Next IML

Lakshmana Rao: "Like what IML did ten years ago, we hope pharma will be able to do for our company in terms of improving the EBITDA especially, and taking us forward in revenue growth later."

Patent Defence & Q PACK Moat

Lakshmana Rao: "We have got the injunction orders against a couple of duplicators. We have copied our container as it is and manufacturing them in a very unscrupulous, unhygienic atmosphere and offering lower prices, impacting our margins indirectly and also our market size."

Capacity Expansion & New Plants


Seasonality & Near-Term Outlook


Guidance & Commitments

CommitmentSpecificsTimeline
Pharma commercial productionOne line starting December, all four segments by JanuaryDec 2023 / Jan 2024
Panipat plant commercial productionTrials December, production JanuaryJan 2024
Cheyyar plant suppliesTrials January, ready end-Jan/early-FebJan-Feb 2024
Mahad plant first phaseConstruction starts December, production by June-JulyJun-Jul 2024
Panipat F&F plantBasic machinery of 4-6 machines set upFeb-Mar 2024
ABG plants (Panipat & Payur)Production startEnd Dec 2023 / early Jan 2024
Full-year volume growthDouble-digit, around 14-15% in Q3, may slip to 8-9%FY24
Food & FMCG H2 growthMore than 20-25%H2 FY24
EBITDA per kg (current year)Continue in ₹37-38 range; Q4 may look up a bit due to pharmaFY24
EBITDA per kg (next year)Target ₹41-42 range with pharma addition and north plant F&F improvementFY25
Pharma revenue₹60-70 crores achievable with starting product mix; utilization clarity by end-MarchFY25 (initial)
Pharma EBITDA per kgAt least ₹150 per kg averageFrom commencement
FY25 volume growth18-20% rangeFY25
Lubricant growth7-10% annualNext 1-2 years
Q PACK growth30-40% at leastOngoing
Food & FMCG growth25% guidance maintainedNext couple of years
Export contribution3-5% of sales3-5 years
Capacity55,000-57,000 tonsEnd FY24

Key Metrics

MetricQ2 FY24
Volume growth~5% YoY, flattish quarter
Half-year volume growth3.4%
Revenue — Paint₹78.3 cr, tonnage 4,460
Revenue — Lubes₹37.7 cr, tonnage 2,162
Revenue — Food & FMCG₹32.86 cr, tonnage 1,040
Revenue — Q PACK₹19.1 cr, tonnage 1,117
IML share62% of volume, 66.7% of value
EBITDA per kg₹37.2 in Q2, ₹38 in H1
Gross profit per kg₹83, down from ~₹89 (per an analyst's math)
Manpower cost increase>14% YoY, driven by staffing for new plants
Rejection rate4–5%, up from ~2% previously due to RCP material adoption
Food & FMCG volume growth15% YoY in Q2, 14% in H1
Paint volume decline~8% YoY, partly due to dropping low-end customers
Satara plant utilization~60%
Capex spent in H1 FY24~₹54 cr
Full-year capex plan₹120–125 cr, with ₹20 cr term loan from Citibank
Installed capacity by end of FY2455,000–57,000 tons, up from 45,000 tons at beginning of FY24
Pharma capacity revenue potential₹60–70 cr turnover with starting product mix
Pharma EBITDA per kg targetat least ₹150
Export turnover₹5–6 cr, <1% of overall sales
Full-year volume growth guidance8–9% possible, double-digit still targeted
FY25 EBITDA per kg target₹41, plus/minus 1